Phase II Study Of Single-Agent SU011248 In The Treatment Of Patients With Renal Cell Carcinoma.

Trial Profile

Phase II Study Of Single-Agent SU011248 In The Treatment Of Patients With Renal Cell Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Mar 2010 Overall survival (OS) and updated results data presented at ASCO 2010 Genitourinary Cancers Symposium.
    • 12 May 2009 Actual end date changed from Oct 2008 to Feb 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top